トリパリマブ併用療法 シスプラチン併用なしの鼻がん: DIAMOND ランダム化臨床試験
, Cheng Xu1, Xiao-Yu Liang1
1Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong, People's Republic (PR) of China.
JAMA
|August 21, 2025
まとめ
トリパリマブ免疫療法とシスプラチン併用は,鼻がん (NPC) の治療に有効で安全である. このアプローチは嘔吐を大幅に減らし,障害のない生存を維持しながら生活の質を改善します.
科学分野:
- 腫瘍学
- 免疫療法
- 臨床試験
背景:
- 鼻がん (NPC) の治療には,しばしば有毒なシスプラチンが併用されます.
- トリパリマブによるプログラム細胞死タンパク質1 (PD-1) 阻害は,潜在的な代替案です.
研究 の 目的:
- トリパリマブを誘導化学療法と放射線療法と併用して,同時期にシスプラチンを除き,局所的に進行したNPCの有効性と安全性を評価する.
- この戦略が標準治療と比較して生存を危うくするかどうかを評価する.
主な方法:
- 局所的に進行したNPCの患者532人を対象とした3期,オープン,多センター,ランダム化臨床試験 (NCT04907370).
- 患者はトリパリマブと誘導化学療法と放射線療法を受け,一グループはシスプラチンを併用し,もう一グループはシスプラチンを併用しなかった.
- コプライマリーエンドポイントは,無故障生存率と全級嘔吐の発生率でした.
主要な成果:
- 同時期にシスプラチン投与を控えたグループは,不発症のない生存率が低かった (3年後の88. 3% vs 87. 6%).
- すべてのグレードの嘔吐の発生率は,シスプラチン投与を控えたグループで有意に低かった (26. 2% vs 59. 8%).
- シスプラチン治療の腕では,患者の報告した生活の質と耐性改善が観察されました.
結論:
- トリパリマブを併用してシスプラチンを投与しない治療は,局所的に進行したNPCの実現可能で非常に効果的な治療である.
- このアプローチは,有毒性,特に嘔吐を大幅に減らすことで,高い無故障生存率を達成します.
- 治療経験と治療結果を改善するために,この患者集団でシスプラチン併用を省略することを支持しています.
関連する概念動画
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K